Industry News Roundup
This article was originally published in The Tan Sheet
Executive Summary
Acetaminophen skin reacting warning in draft guidance; supplement ingredient testing exemption option continues; FTC breaks Habitrol from GSK/Novartis JV; NARB stops clock on Mucinex 8-minute claim; kick start for ClickStick; NVC drinks up Blu-Dot; drug claims, GMP problems for Avena Botanicals; Ugam beefs up MusclePharm price monitoring; Nutraceutical International growth trims income; SDC Nutrition on global mission; and Naturally Splendid acquires Full Spectrum technology.
You may also be interested in...
Unilever Plan To Grow Consumer Health By Acquisition, Meet US Tightening Of Merger Scrutiny
Unilever, which has had three offers for GSK rebuffed, likely notes that the Federal Trade Commission and Department of Justice signal they will tighten scrutiny of deals that merge companies providing consumer-facing products and services.
Supplement Firms Confounded By Identity Testing Waiver Process
FDA says it has not received any petitions to request an exemption from the 100% supplement ingredient identity testing requirement. Food and drug attorneys say the hassle of preparing a petition for a waiver outweighs the potential benefits
In Brief: Acetaminophen Warnings, OTC HSA Bill, Durbin’s Supplement Reg Bill
FDA adds acetaminophen warnings; CHPA suggests 4-aminophenol standard; OTC HSA bill in House; supplement registration bill reintroduced; FSMA user fees still on hold; more scrutiny of energy drinks; and Public Citizen pans OTC Oxytrol.